CTRI/2023/07/055367
Not yet recruiting
Phase 2
Experimental and Clinical Evaluation of Antiallergic Effect of Talishadi Churna & Talishadi Arka in Allergic Respiratory Tract Diseases. - Nil
Dean and Principal of Parul Institute of Ayurved0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dean and Principal of Parul Institute of Ayurved
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients of either gender with age group 20\-65 Years (both years inclusive).
- •2\) Elevated level of IGM \&IGE mild and moderate
- •3\) Patients having clinical features of Allergic Rhinitis
- •4\) Patients having clinical features of Bronchial asthma
Exclusion Criteria
- •1\) Known case of any chronic and severe systemic disorder including IHD, CVA, uncontrolled
- •Hypertension, uncontrolled diabetes, CRF, Active Malignancy Disease.
- •2\) Pregnant and lactating females.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinicall Research of Sarafua-MaskMask dermatitisJPRN-UMIN000044476Department of Dermatology, Kochi Medical school, Kochi University50
Active, not recruiting
Phase 1
Observational study in allergic patients to treating hay fever against grass pollen.Patient reported outcome in patients treated with various doses of Depigoid Phleum.Allergic rhinitis/rhinoconjunctivitis with or without concomitant asthma due to grass pollen allergyMedDRA version: 14.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853MedDRA version: 14.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 100000004855MedDRA version: 14.1Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 100000004855Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2013-004920-12-CZETI Pharma GmbH275
Completed
Not Applicable
Evaluation of efficacy of anti-allergic ophthalmic solution for allergic conjunctival diseases using the allergic conjunctival disease medical treatment assessment system.JPRN-UMIN000013173Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine.60
Recruiting
Phase 2
Subcutaneous immunotherapy with PROLINEM-DS-Asthma- Adults-Fase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000278ational Center of Bioproducts (BioCen)60
Completed
Not Applicable
on-interventional study of Allergy immunotherapy in adult patients with House dust mite allergyHouse dust mite allergyJ30.3J45Other allergic rhinitisAsthmaDRKS00009983ALK-Abelló Arzneimittel GmbH1,525